<div id="readability-page-1"><div><p>Over the last 7 days, the United States market has dropped by 2.5%, yet it has risen by 23% over the past year, with earnings expected to grow by 17% annually in the coming years. In this context of fluctuating performance and anticipated growth, stocks with high insider ownership can be appealing as they often signal confidence from those closest to the company's operations and potential for substantial earnings growth.</p><h3>Top 10 Growth Companies With High Insider Ownership In The United States</h3><div><table><tbody><tr><td><strong>Name</strong></td><td><strong>Insider Ownership</strong></td><td><strong>Earnings Growth</strong></td></tr><tr><td>Uxin (UXIN)</td><td>34.3%</td><td>74.1%</td></tr><tr><td>Upstart Holdings (UPST)</td><td>14.1%</td><td>57.3%</td></tr><tr><td>On Holding (ONON)</td><td>26%</td><td>23.1%</td></tr><tr><td>KVH Industries (KVHI)</td><td>16.3%</td><td>146.1%</td></tr><tr><td>Karman Holdings (KRMN)</td><td>15.6%</td><td>52.6%</td></tr><tr><td>Duos Technologies Group (DUOT)</td><td>11.2%</td><td>158.4%</td></tr><tr><td>Corcept Therapeutics (CORT)</td><td>11.7%</td><td>48.9%</td></tr><tr><td>Astera Labs (ALAB)</td><td>10.3%</td><td>29.3%</td></tr><tr><td>AppLovin (APP)</td><td>27.4%</td><td>21.7%</td></tr><tr><td>Abeona Therapeutics (ABEO)</td><td>16.7%</td><td>32.9%</td></tr></tbody></table></div><p>Click here to see the full list of 176 stocks from our Fast Growing US Companies With High Insider Ownership screener.</p><p>Below we spotlight a couple of our favorites from our exclusive screener.</p><h2>ImmunityBio (IBRX)</h2><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p><p><strong>Overview:</strong> ImmunityBio, Inc. is a biotechnology company dedicated to developing and commercializing advanced immunotherapies aimed at enhancing the immune system's response to cancer and infectious diseases, with a market cap of approximately $7.25 billion.</p><p><strong>Operations:</strong> The company generates revenue of $140.98 million from its segment focused on developing next-generation therapies.</p><p><strong>Insider Ownership:</strong> 28.2%</p><p><strong>Earnings Growth Forecast:</strong> 64.1% p.a.</p><p>ImmunityBio, a growth-focused company with significant insider ownership, is advancing its ANKTIVA treatment for BCG-unresponsive non-muscle invasive bladder cancer. Recent FDA acceptance of its supplemental Biologics License Application could expand ANKTIVA's indications. Despite expected revenue growth of 47.8% annually, ImmunityBio faces financial challenges with less than a year of cash runway and recent shareholder dilution. Analysts agree on potential stock price appreciation, though the company currently trades significantly below estimated fair value.</p><ul><li>Unlock comprehensive insights into our analysis of ImmunityBio stock in this growth report.</li><li>Upon reviewing our latest valuation report, ImmunityBio's share price might be too pessimistic.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b2d6e0fd-dc1f-4014-8f92-60363368b53b/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b2d6e0fd-dc1f-4014-8f92-60363368b53b/chart/earnings-and-revenue-growth"/><figcaption>IBRX Earnings and Revenue Growth as at Jun 2026</figcaption></figure><h2>Li Auto (LI)</h2><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p><p><strong>Overview:</strong> Li Auto Inc. operates in the energy vehicle market in the People’s Republic of China with a market cap of approximately $14.48 billion.</p><p><strong>Operations:</strong> Li Auto generates revenue primarily from its auto manufacturing segment, totaling CN¥109.37 billion.</p><p><strong>Insider Ownership:</strong> 33%</p><p><strong>Earnings Growth Forecast:</strong> 61.6% p.a.</p><p>Li Auto, characterized by high insider ownership, is navigating growth amid challenges. The company forecasts a 13% annual revenue increase, outpacing the US market. However, recent earnings revealed a net loss of CNY 2.29 billion for Q1 2026 despite vehicle deliveries reaching over 1.7 million year-to-date. Li Auto's strategic moves include a US$1 billion share buyback and launching new models like the Li L9 to bolster its position in the competitive electric vehicle sector.</p><ul><li>Take a closer look at Li Auto's potential here in our earnings growth report.</li><li>Our expertly prepared valuation report Li Auto implies its share price may be too high.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9eb69e11-e6b7-42a1-afa3-9f2354e8ac7f/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9eb69e11-e6b7-42a1-afa3-9f2354e8ac7f/chart/ownership-breakdown"/><figcaption>LI Ownership Breakdown as at Jun 2026</figcaption></figure><h2>Ethos Technologies (LIFE)</h2><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p><p><strong>Overview:</strong> Ethos Technologies Inc. operates as a third-party administrator for insurance policies in the United States and has a market cap of approximately $1.06 billion.</p><p><strong>Operations:</strong> The company generates revenue primarily from its insurance broker services, amounting to $485.82 million.</p><p><strong>Insider Ownership:</strong> 22%</p><p><strong>Earnings Growth Forecast:</strong> 94.5% p.a.</p><p>Ethos Technologies, with significant insider ownership, is expanding its digital life insurance offerings through strategic partnerships and technological advancements. Recent collaborations with Liberty Mutual and Banner Life Insurance enhance Ethos' reach and product portfolio. Despite a Q1 2026 net loss of US$166.39 million, revenue surged to US$193.1 million from the previous year. The launch of a ChatGPT app signifies their innovative approach to consumer engagement in the evolving insurance landscape, although insider selling has been noted recently.</p><ul><li>Navigate through the intricacies of Ethos Technologies with our comprehensive analyst estimates report here.</li><li>Upon reviewing our latest valuation report, Ethos Technologies' share price might be too optimistic.</li></ul><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fbc02edd-aafc-4f38-aa18-ae0098f75905/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/fbc02edd-aafc-4f38-aa18-ae0098f75905/chart/earnings-and-revenue-growth"/><figcaption>LIFE Earnings and Revenue Growth as at Jun 2026</figcaption></figure><h2>Seize The Opportunity</h2><ul><li>Click this link to deep-dive into the 176 companies within our Fast Growing US Companies With High Insider Ownership screener.</li><li>Curious About Other Options? This technology could replace computers: discover the 30 stocks are working to make quantum computing a reality.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data      and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your      financial situation. We aim to bring you long-term focused analysis driven by fundamental data.      Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.      Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders.      It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities.      All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p><div><h3>Valuation is complex, but we're here to simplify it.</h3><p>Discover if Ethos Technologies might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><p>Access Free Analysis</p></div></div></div>

LIFE

IBRX

<p>The article highlights US growth companies with high insider ownership, such as ImmunityBio, Li Auto, and Ethos Technologies, noting their potential for substantial earnings growth. It provides an overview of these firms' operations, insider stakes, and financial forecasts, while cautioning that the content is general analysis based on historical data and not financial advice.</p>

3 Growth Companies With High Insider Ownership Seeing Up To 94% Earnings Growth